Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib dose reduction versus continuation in ulcerative colitis remission
NL-OMON50221Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib in autoimmune colitis (2 arms), sponsored by Pfizer. Primary endpoint: Remission based on modified Mayo score at Month 6. Started Dec 2018; status: active, not recruiting.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON50221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50221.